AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sl… Read more
AlzeCure Pharma (ALZCUR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.150x
Based on the latest financial reports, AlzeCure Pharma (ALZCUR) has a cash flow conversion efficiency ratio of -0.150x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.62 Million) by net assets (Skr50.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AlzeCure Pharma - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how AlzeCure Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AlzeCure Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AlzeCure Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
iZafe Group AB Series B
ST:IZAFE-B
|
-0.175x |
|
Healthconn Corp.
TWO:6665
|
0.072x |
|
Asia Precision Public Company Limited
BK:APCS
|
0.070x |
|
Thai Rubber Latex Group Public Company Limited
BK:TRUBB
|
-0.011x |
|
Rocky Mountain Chocolate Factory
NASDAQ:RMCF
|
-0.206x |
|
Wellysun Inc
TW:6988
|
0.073x |
|
Radhika Jeweltech Limited
NSE:RADHIKAJWE
|
0.003x |
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
-0.438x |
Annual Cash Flow Conversion Efficiency for AlzeCure Pharma (2017–2024)
The table below shows the annual cash flow conversion efficiency of AlzeCure Pharma from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr26.18 Million | Skr-35.12 Million | -1.341x | -1143.15% |
| 2023-12-31 | Skr23.77 Million | Skr3.06 Million | 0.129x | +107.78% |
| 2022-12-31 | Skr60.48 Million | Skr-99.91 Million | -1.652x | +22.89% |
| 2021-12-31 | Skr32.97 Million | Skr-70.64 Million | -2.142x | -241.35% |
| 2020-12-31 | Skr110.75 Million | Skr-69.51 Million | -0.628x | -127.15% |
| 2019-12-31 | Skr182.01 Million | Skr-50.28 Million | -0.276x | -77.59% |
| 2018-12-31 | Skr233.17 Million | Skr-36.27 Million | -0.156x | +4.26% |
| 2017-12-31 | Skr51.83 Million | Skr-8.42 Million | -0.162x | -- |